Health Trials

Progressive Metastatic Castrate Resistant Prostate Cancer

1

Review clinical trials related to Progressive Metastatic Castrate Resistant Prostate Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

Participants needed: 188
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 21, 2026Locations: 35
Eligibility criteria

Participant is an adult man ≥ 18 years of age. [+9]

Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 in... [+6]

Read more